Venture Capital

Latest Headlines

Latest Headlines

Euro VC veteran gathers €63M for Belgium-based life science fund

Belgian VC shop V-Bio Ventures has raised €63 million ($67 million) to invest in life science startups. The newly formed fund has a remit to back new and emerging biotechs from across Europe, but with strong ties to VIB, the Belgian research institute that spawned Ablynx, is likely to funnel a chunk of its cash into local companies.

Molecular Health raises $27M to advance data-crunching tech

Molecular Health has raised $27 million to drive adoption of its data-crunching technology, which includes a tool aimed at drug developers. The investment moves the sum raised by Molecular Health to date beyond the $100 million mark.

Silicon Valley VC shop Andreessen Horowitz sets up $200M bio fund

Andreessen Horowitz is joining the rush of Silicon Valley investors looking for gold in biotech. The renowned VC shop has rounded up $200 million, poached a professor from Stanford University and given him a brief to ferret out the hottest startups at the intersection of software and biotech.

Ex-Lumena gang pilots new course at Amplyx with antifungal R&D, $40.5M

Some of the old San Diego gang that brought you Lumena--bought out by Shire last year--have moved into top positions at Amplyx Pharmaceuticals as the biotech heads in a new direction, pointing a recently in-licensed antifungal product toward the clinic with $40.5 million from a high-profile group of venture players.

MiRagen captures a $41M round for a pair of microRNA trials

Boulder, CO-based miRagen Therapeutics has scooped up a $41 million C round designed to get its lead microRNA drugs into the clinic in the hunt for some convincing proof-of-concept data.

NEA joins a $35M round for a Wellcome-backed gene therapy player

After posting some early clinical success with its first gene therapy project, University of Oxford spinout NightstaRx is looking to widen its pipeline of projects, recruiting venture giant New Enterprise Associates to pitch in on a $35 million funding round.

Targeting ALS, GlaxoSmithKline and Avalon seed another build-to-buy startup

Partners GlaxoSmithKline and Avalon Ventures have seeded a 7th startup in their company-building collaboration, lining up $10 million for a new effort to treat ALS.

Flagship launches another microbiome biotech with $35M and a focus on cancer

Flagship Ventures, the group behind microbiome success story Seres Therapeutics, is delving further into gut science with a new startup that aims to treat cancer by harnessing the power of the body's many bacterial tenants.

Gates, Hopp back $110M megaround for CureVac's mRNA work

The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac, a German mRNA biotech which has now garnered some $330 million in support.

Marquee VCs back a $40M round for Crinetics' acromegaly drug

A group of marquee venture investors has joined forces to back a $40 million Series A for Crinetics Pharmaceuticals, an early-stage biotech in San Diego that has been working on a next-gen oral treatment for acromegaly.